Serum betatrophin levels are significantly increased in obese patients compared to lean patients regardless to the presence of PCOS

References

• Yi P, Park J-S, Melton DA. Betatrophin: a hormone that controls pancreatic β cell proliferation. Cell. 2013;153(4):747–758.
   PubMed Web of Science ®Google Scholar
• Zhang R. Lipasin, a novel nutritionally-regulated liver-enriched factor that regulates serum triglyceride levels. Biochem Biophys Res Commun. 2012;424(4):786–792.
   PubMed Web of Science ®Google Scholar
• Dong XY, Pang XW, Yu ST, et al. Identification of genes differentially expressed in human hepatocellular carcinoma by a modified suppression subtractive hybridization method. Int J Cancer. 2004;112(2):239–248.
   PubMed Web of Science ®Google Scholar
• Quagliarini F, Wang Y, Kozlitina J, et al. Atypical angiopoietin-like protein that regulates ANGPTL3. Proc Natl Acad Sci USA. 2012;109(48):19751–19756.
   PubMed Web of Science ®Google Scholar
• Ren G, Kim JY, Smas CM. Identification of RIFL, a novel adipocyte enriched insulin target gene with a role in lipid metabolism. Am J Physiol Endocrinol Metab. 2012;303(3):E334–E351.
   PubMed Web of Science ®Google Scholar
• Erbag G, Eroglu M, Turkon H, et al. Relationship between betatrophin levels and metabolic parameters in patients with polycystic ovary syndrome. Cell MolBiol (Noisy-le-Grand). 2016;62(5):20–24.
   PubMed Web of Science ®Google Scholar
• Calan M, Yilmaz O, Kume T, et al. Elevated circulating levels of betatrophin are associated with polycystic ovary syndrome. Endocrine. 2016;53(1):271–279.
   PubMed Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19–25.
   Web of Science ®Google Scholar
• Tena G, Moran C, Romero R, et al. Ovarian morphology and endocrine function in polycystic ovary syndrome. Arch Gynecol Obstet. 2011;284(6):1443–1448.
   PubMed Web of Science ®Google Scholar
• Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser. 2000;894:i–xii.
   PubMed Web of Science ®Google Scholar
• Fu Z, Berhane F, Fite A, et al. Elevated circulating lipasin/betatrophin in human type 2 diabetes and obesity. Sci Rep. 2015;4(1):5013.
   Google Scholar
• Fenzl A, Itariu BK, Kosi L, et al. Circulating betatrophin correlates with atherogenic lipid profiles but not with glucose and insulin levels in insulin-resistant individuals. Diabetologia. 2014;57(6):1204–1208.
   PubMed Web of Science ®Google Scholar
• Gómez-Ambrosi J, Pascual E, Catalán V, et al. Circulating betatrophin concentrations are decreased in human obesity and Type 2 diabetes. J Clin Endocrinol Metab. 2014;99(10):E2004–9.
   PubMed Web of Science ®Google Scholar
• Erol O, Ellidağ HY, Ayık H, et al. Evaluation of circulating betatrophin levels in gestational diabetes mellitus. Gynecol Endocrinol. 2015;31(8):652–656.
   PubMed Web of Science ®Google Scholar
• Erol O, Özel MK, Ellidağ HY, et al. Assessment of circulating betatrophin concentrations in lean glucose-tolerant women with polycystic ovary syndrome. J Obstet Gynaecol. 2017;37(5):633–638.
   PubMedGoogle Scholar
• Li L, Zhang F, Cui J, et al. Association of betatrophin with metabolic characteristics in overweight/obese and lean women with PCOS. Gynecol Endocrinol. 2017;33(3):238–243.
   PubMed Web of Science ®Google Scholar
• Eksi Haydardedeoglu F, Bagir GS, Haydardedeoglu B, et al. Serum betatrophin levels are reduced in patients with full-blown polycystic ovary syndrome. Gynecol Endocrinol. 2019;35(3):224–227.
   PubMed Web of Science ®Google Scholar
• Sahin Ersoy G, Altun Ensari T, Vatansever D, et al. Novel adipokines WISP1 and betatrophin in PCOS: relationship to AMH levels, atherogenic and metabolic profile. Gynecol Endocrinol. 2017;33(2):119–123.
   PubMed Web of Science ®Google Scholar
• Varikasuvu SR, Panga JR, Satyanarayana MV. Circulating Angiopoietin-like 8 protein (ANGPTL8/Betatrophin) in patients with polycystic ovary syndrome: a systematic review and multi effect size meta-analysis. Gynecol Endocrinol. 2019;35(3):190–197.
   PubMed Web of Science ®Google Scholar
• Reyes-Muñoz E, Ortega-González C, Martínez-Cruz N, et al. Association of obesity and overweight with the prevalence of insulin resistance, pre-diabetes and clinical-biochemical characteristics among infertile Mexican women with polycystic ovary syndrome: a cross-sectional study. BMJ Open. 2016;6(7):e012107.
   PubMed Web of Science ®Google Scholar
• Li X, Lin JF. [Clinical features, hormonal profile, and metabolic abnormalities of obese women with obese polycystic ovary syndrome]. Zhonghua Yi Xue Za Zhi. 2005;85(46):3266–3271.
   PubMedGoogle Scholar
• Layegh P, Mousavi Z, Farrokh Tehrani D, et al. Insulin resistance and endocrine-metabolic abnormalities in polycystic ovarian syndrome: comparison between obese and non-obese PCOS patients. IJRM. 2016;14(4):263–270.
   Google Scholar
• Kumar A, Woods KS, Bartolucci AA, Azziz R. Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS). Clin Endocrinol. 2005;62(6):644–649.
   PubMed Web of Science ®Google Scholar
• Holte J, Bergh T, Gennarelli G, et al. The independent effects of polycystic ovary syndrome and obesity on serum concentrations of gonadotropins and sex steroids in premenopausal women. Clin Endocrinol. 1994;41(4):473–481.
   PubMed Web of Science ®Google Scholar
• Saito K, Matsuzaki T, Iwasa T, et al. Steroidogenic pathways involved in androgen biosynthesis in eumenorrheic women and patients with polycystic ovary syndrome. J Steroid Biochem Mol Biol. 2016;158:31–37.
   PubMed Web of Science ®Google Scholar
• Pinola P, Piltonen TT, Puurunen J, et al. Androgen profile through life in women with polycystic ovary syndrome: a nordic multicenter collaboration study. J Clin Endocrinol Metab. 2015;100(9):3400–3407.
   PubMed Web of Science ®Google Scholar